PhoenixBio Co., Ltd. (6190.T)
JPY 324.0
(1.25%)
JPY 324.0
(1.25%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -660.96 Million JPY | -55.39% |
| 2022 | -425.35 Million JPY | -48.42% |
| 2021 | -286.58 Million JPY | 0.87% |
| 2020 | -289.11 Million JPY | 36.8% |
| 2019 | -457.44 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -930 Million JPY | -40.7% |
| 2023 Q4 | -660.96 Million JPY | 25.08% |
| 2023 Q3 | -882.26 Million JPY | -4.08% |
| 2023 Q1 | -551.14 Million JPY | -29.57% |
| 2023 Q2 | -847.69 Million JPY | -53.81% |
| 2023 FY | -660.96 Million JPY | -55.39% |
| 2022 Q3 | -699 Million JPY | -38.77% |
| 2022 Q2 | -503.7 Million JPY | 0.0% |
| 2022 Q4 | -425.35 Million JPY | 39.15% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 188.987% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | 41.711% |
| GNI Group Ltd. | -17.93 Billion JPY | 96.314% |
| Linical Co., Ltd. | -4.46 Billion JPY | 85.191% |
| Trans Genic Inc. | -221.16 Million JPY | -198.848% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 84.958% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 86.201% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 146.107% |
| AnGes, Inc. | -3.79 Billion JPY | 82.596% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -57.07% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 102.654% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -32.682% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -41.731% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 75.575% |
| CanBas Co., Ltd. | -1.88 Billion JPY | 64.995% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | 32.702% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 80.543% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | 36.112% |
| Kidswell Bio Corporation | 343.58 Million JPY | 292.369% |
| PeptiDream Inc. | 3.29 Billion JPY | 120.078% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | 32.041% |
| Ribomic Inc. | -2.09 Billion JPY | 68.522% |
| SanBio Company Limited | -3.78 Billion JPY | 82.559% |
| Healios K.K. | -2.19 Billion JPY | 69.819% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | 30.047% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 74.812% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | 53.357% |
| StemRIM | -8.41 Billion JPY | 92.141% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 85.887% |
| FunPep Company Limited | -1.79 Billion JPY | 63.144% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | 69.063% |
| Stella Pharma Corporation | -1.11 Billion JPY | 40.954% |
| TMS Co., Ltd. | -3.44 Billion JPY | 80.823% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 88.103% |
| Cuorips Inc. | -5.56 Billion JPY | 88.114% |
| K Pharma,Inc. | -3.26 Billion JPY | 79.765% |
| Takara Bio Inc. | -32.2 Billion JPY | 97.948% |
| ReproCELL Incorporated | -2.93 Billion JPY | 77.511% |
| StemCell Institute Inc. | -2.83 Billion JPY | 76.7% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | 68.013% |
| CellSeed Inc. | -2.01 Billion JPY | 67.15% |